Guo Lijing, Li Zonghan, Luo Bin, Bai Yizhou
Department of General Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua, China.
Medicine (Baltimore). 2025 Apr 18;104(16):e42126. doi: 10.1097/MD.0000000000042126.
A totally implantable venous access port is a subcutaneously implantable, long-term infusion device first reported by Niederhuber in 1982.
totally implantable venous access port provides a reliable venous access route for patients requiring long-term infusion therapy and chemotherapy.
Due to its advantages of fewer complications, low infection rates, and ease of long-term use, it has become the primary choice for central venous access in breast cancer chemotherapy patients.
In 2021, both the American Society of Vascular Access and the European Society for Medical Oncology recommended the optimal position for the catheter tip to beat the cavoatrial junction, where the superior vena cava meets the right atrium. Similarly, domestic guidelines also recommend the cavoatrial junction as the ideal position for the catheter tip.
Infusion port catheter malposition, where the catheter tip is located in vessels other than the superior vena cava, is a rare complication of port implantation. This can lead to infusion difficulties or port-related thrombosis.
Therefore, timely intraoperative identification of catheter malposition and effective adjustment is of significant clinical value.
完全植入式静脉通路端口是一种可皮下植入的长期输液装置,由尼德胡伯于1982年首次报道。
完全植入式静脉通路端口为需要长期输液治疗和化疗的患者提供了可靠的静脉通路。
由于其并发症少、感染率低、易于长期使用等优点,它已成为乳腺癌化疗患者中心静脉通路的首选。
2021年,美国血管通路协会和欧洲医学肿瘤学会均推荐导管尖端的最佳位置是在上腔静脉与右心房交汇处的腔房交界处。同样,国内指南也推荐腔房交界处作为导管尖端的理想位置。
输液港导管位置不当,即导管尖端位于上腔静脉以外的血管中,是港植入术的一种罕见并发症。这可能导致输液困难或与港相关的血栓形成。
因此,术中及时识别导管位置不当并进行有效调整具有重要的临床价值。